- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04674319
Attending to External Cues and Movement Strategies in Parkinson Disease
Attending to External Cues and Movement Strategies in Parkinson Disease: Feasibility in Ecological Setting.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
External cues and cognitive movement strategies are common compensatory modes that people with Parkinson's disease can use to overcome typical gait disturbances. It is suggested that these modes utilize alternative neural pathways, bypassing the impaired basal ganglia motor circuits in the brain. In addition, both compensatory modes, in particular the movement cognitive strategies, are suggested to rely on attentional mechanisms.
Cognitive deficits are common in PwP and include among others, impairment of attention, particularly in tasks requiring internal control of attention. Considering that gait compensatory modes may rely on cognitive function, in particular the cognitive movement strategies, it is not clear whether People with Parkinson's disease can engaged with these strategies for a prolonged time or distance as in many cases required in daily living.
Therefore, the objectives of this study are 1) to test the effect of compensatory modes- external cueing and cognitive movement strategy on gait in prolonged walking. 2) to test whether people with Parkinson's disease can stay engaged and focus their attention to these compensatory modes for prolonged time. 3) to test whether subject's cognitive function is related to the ability to stay engaged with these compensatory modes. Subjects are recruited from a community physical- therapy groups for people with Parkinson's disease. Healthy older adults will be recruited from the community and will serve as a control group. Participants are invited for two separate evaluation sessions that includes: 1. Assessment of background characteristic: demographic details, severity of disease ( assessed by the Unified Parkinson's Disease Rating Scale-UPDRS), Levodopa Equivalent Dose (LED), freezing of gait questionnaire (FOG-Q) and Montreal cognitive assessment (MoCA).
2. Evaluation of gait while attending to external cues and cognitive movement strategy.
3. Evaluation of brain engagement during gait 4. Computerized cognitive assessment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Please Select...
-
Haifa, Please Select..., Israel, 3498838
- Galit Yogev-Seligmann
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria for people with Parkinson's disease:
- Diagnosis of Parkinson's disease
- Age of 50-85
- Able to walk independently in daily lives.
Inclusion Criteria for the control group:
- Age of 50-85
- Able to walk independently in daily lives.
Exclusion Criteria for people with Parkinson's disease:
- Use of assistive hearing device
- Suffer of hearing impairment (by self-declaration)
- Suffer of dementia (MoCa test score above 21)
- Suffer of any orthopedic condition
- Pains or other health condition that may affect gait except of PD
Exclusion Criteria for the control group:
- Use of assistive hearing device
- Suffer of hearing impairment (by self-declaration)
- Suffer of dementia (MoCa test score above 21)
- Suffer of any orthopedic condition
- Pains or other health condition that may affect gait
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Brain engagement while using compesatory modes for walking
Brain engagemnent (recruitment of attention) is measured during four walking conditions
|
external cueing are sensory stimuli such as auditory (e.g. rhythmic metronome beats) or or visual (e.g. spaced lines on the floor). Cognitive movement strategies refer to focusing attention on a specific parameter of gait (e.g. step length, arm swing). In the study participants walk under four walking conditions:1)usuall (baseline) walking 2)walking while attending to external cues wich will be applied via metronome beats. The number of beats per minute is adjusted to each participant's steps number per minute. 3)walking with movement cognitive strategy: participants are requested to focus on their step length- and focus on increasing their step length while walking 4) Dual tasking-walking while performing a cognitive task. During the four walking conditions Brain engegament will be measured, using the single-channel EEG system (Brain-MARC LTD) described in the follwing outcomes measures section. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait speed- Physiological measurement of gait
Time Frame: Through study completion, an average of 1 year
|
Gait speed is measured with the Mobility Lab OPAL system (APDM, USA) consisting of three small inertial measurement units (IMU sensors including 3D accelerometers and 3D gyroscopes sampled at 128 Hz, MobilityLab, APDM Inc., Portland, OR).
IMUs were attached at the participant's ankles, and lumbar region using elastic Velcro straps.
These sensors are measuring gait speed (meters per second).
|
Through study completion, an average of 1 year
|
Step length- Physiological measurement of gait
Time Frame: Through study completion, an average of 1 year
|
Step length is measured with the Mobility Lab OPAL system (APDM, USA) consisting of three small inertial measurement units (IMU sensors including 3D accelerometers and 3D gyroscopes sampled at 128 Hz, MobilityLab, APDM Inc., Portland, OR).
IMUs were attached at the participant's ankles, and lumbar region using elastic Velcro straps.
These sensors are measuring step length (cm).
|
Through study completion, an average of 1 year
|
Cadence- Physiological measurement of gait
Time Frame: Through study completion, an average of 1 year
|
Cadence is measured with the Mobility Lab OPAL system (APDM, USA) consisting of three small inertial measurement units (IMU sensors including 3D accelerometers and 3D gyroscopes sampled at 128 Hz, MobilityLab, APDM Inc., Portland, OR).
IMUs were attached at the participant's ankles, and lumbar region using elastic Velcro straps.These sensors are measuring cadence (number of steps taken in 1 minute).
|
Through study completion, an average of 1 year
|
Swing time percent- Physiological measurement of gait
Time Frame: Through study completion, an average of 1 year
|
Swing time percent (the percent of time from the total time of one gait cycle that one leg is in the air is measured with the Mobility Lab OPAL system (APDM, USA) consisting of three small inertial measurement units (IMU sensors including 3D accelerometers and 3D gyroscopes sampled at 128 Hz, MobilityLab, APDM Inc., Portland, OR).
IMUs were attached at the participant's ankles, and lumbar region using elastic Velcro straps.These sensors are measuring swing time percent (unit are given in percents)
|
Through study completion, an average of 1 year
|
Electrical activity (eeg) of the brain-phisyological measure of electircal signals
Time Frame: Through study completion, an average of 1 year
|
During the walking, measure of attention recruitment during walking is applied by a single-channel EEG system (Brain-MARC LTD).
The system simplifies EEG analysis to adjust the extraction of relevant attention-related markers from ongoing EEG.
EEG is sampled using the MindWave dry electrode system [25], with one frontal electrode (∼Fpz) and one reference electrode on the earlobe.
The sampled data are transferred through a wireless connection to the experiment computer, where the signal is processed.
An algorithm is calaculating
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive function Go-NoGo Response Inhibition
Time Frame: Through study completion, an average of 1 year
|
NeuroTrax™ computerized tests assess brain wellness across an array of cognitive domains. Specifically, the Go-NoGo Response Inhibition tests abilities of Attention and Executive Function. The Go-NoGo test is a test of response time and response inhibition. Participants are presented with a series of large colored squares at variable delays. Each square may be one of four colors. Participants are instructed to respond as quickly as possible by pressing a mouse button if the square is any color but red. Outcome parameters include accuracy (i.e., percent correct), response time and its associated variance, a composite score computed as accuracy divided by response time, number of errors of omission, number of errors of commission, and response time associated with errors of commission. |
Through study completion, an average of 1 year
|
Cognitive function-Stroop Interference
Time Frame: Through study completion, an average of 1 year
|
NeuroTrax™ computerized tests assess brain wellness across an array of cognitive domains. Specifically, Stroop Interference tests abilities of Attention, Executive Function. The Stroop test measures response time and executive function. In the test subjects are required to say the color of the word on the screen, not what the word says. Outcome parameters include accuracy, response time and its associated variance, and a composite score computed as accuracy divided by response time. |
Through study completion, an average of 1 year
|
Cognitive function-Staged Information Processing Speed
Time Frame: Through study completion, an average of 1 year
|
NeuroTrax™ computerized tests assess brain wellness across an array of cognitive domains.
Specifically, Staged Information Processing Speed test abilities of Attention and Information Processing Speed.
The Staged Information Processing Speed test measures information processing at increasing levels of complexity.
The test is comprised of three levels of information processing load: single digits, two-digit arithmetic problems (e.g., 5-1), and three-digit arithmetic problems (e.g., 3+2-1).
Participants are presented with a series of digits or arithmetic problems (as per the level) and are instructed to respond as quickly as possible by pressing the left mouse button if the digit or result is less than or equal to 4 and the right mouse button if it is greater than 4. Outcome parameters for each rate increment for each level include accuracy, response time and its
|
Through study completion, an average of 1 year
|
Cognitive function-Finger Tapping
Time Frame: Through study completion, an average of 1 year
|
NeuroTrax™ computerized tests assess brain wellness across an array of cognitive domains.
Specifically, Finger Tapping tests motor skills.
Participants are presented with a white rectangle, which fills with red from left to right over 12 sec.
The task requires the participant to tap the left mouse button as many times as possible while the rectangle fills with red.
The outcome parameters for this test include inter-tap interval and associated variance (in milliseconds) for the participant's dominant hand.
|
Through study completion, an average of 1 year
|
Cognitive function-'Catch' Game
Time Frame: Through study completion, an average of 1 year
|
NeuroTrax™ computerized tests assess brain wellness across an array of cognitive domains.
Specifically, the 'Catch' Game tests abilities of Executive Function and Motor Skills.
During the 'Catch' Game participants see a rectangular white object falling vertically from the top of the screen.
Their task is to "catch" the object before it reaches the bottom of the screen by positioning the rectangular green paddle directly in the path of the falling object.
Responses are made with the participant's best hand.
The rate of the falling object increases incrementally as the test continues making it increasingly difficult to "catch" the object in time.
Outcome parameters include response time and associated variance for the first move, number of direction changes per trial, error for missed catches, and a total performance score.
|
Through study completion, an average of 1 year
|
Cognitive function-Problem Solving
Time Frame: Through study completion, an average of 1 year
|
NeuroTrax™ computerized tests assess brain wellness across an array of cognitive domains.
Specifically,the NeuroTrax Problem Solving test is a non-verbal IQ test that assesses the ability to appreciate the spatial relationships among geometric forms that constitute a pattern.
Participants are presented with an incomplete pattern consisting of three squares containing simple geometric forms in a particular configuration.
Six additional squares containing geometric forms are presented along the bottom of the screen.
Responses with the keyboard number pad indicate which of the six forms best completes the pattern.
The spatial relationships among the simple geometric forms become more complex as the test progresses, and the test is adaptive in that it terminates early when performance is poor.
The outcome parameter for this test consists of a total accuracy score that incorporates performance at differing levels of difficulty.
|
Through study completion, an average of 1 year
|
Cognitive function-executive function index score
Time Frame: Through study completion, an average of 1 year
|
Groups of normalized parameters that measure executive function are averaged to produce index score of executive function.
The Outcome Parameters Comprising this Index Scores are: Go-NoGo: Composite Score; Stroop Interference: Composite Score; Catch Game: Total Score.
|
Through study completion, an average of 1 year
|
Cognitive function-Attention index score
Time Frame: Through study completion, an average of 1 year
|
Groups of normalized parameters that measure attention are averaged to produce index score of attention.
The Outcome Parameters Comprising this Index Scores are: Go-NoGo: Response Time; Go-NoGo: Response Time Standard Deviation; Stroop Interference: Response Time; Staged Info Processing: Response Time; Information Processing: Accuracy.
|
Through study completion, an average of 1 year
|
Cognitive function-Information Processing Speed index score
Time Frame: Through study completion, an average of 1 year
|
Groups of normalized parameters that measure Information Processing Speed are averaged to produce index score of Information Processing Speed.
The Outcome Parameters Comprising this Index Scores are: Staged Information Processing: Composite Score, Level 1.1; Staged Information Processing: Composite Score, Level 1.3; Staged Information Processing: Composite Score, Level 2.1; Staged Information Processing: Composite Score, Level 2.2
|
Through study completion, an average of 1 year
|
Cognitive function-motor skills index score
Time Frame: Through study completion, an average of 1 year
|
Groups of normalized parameters that measure motor skills are averaged to produce index score of motor skills.
The Outcome Parameters Comprising this Index Scores are: Finger Tapping: Inter-Tap Interval; Finger Tapping: Tap Interval Std Dev; Catch Game: Time to Make 1st Move
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 052/19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on external cues and cogntive movement strategies
-
Massachusetts General HospitalRecruitingSuicideUnited States
-
Hasselt UniversityRevalidatie & MS Centrum Overpelt; National MS Center MelsbroekRecruitingMultiple Sclerosis | Cerebral LesionBelgium